Physician profile
Siddharth Sheth
NPI 1982947008
$33,255.59
in general payments reported to CMS, 2019-2025
14 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,401 · 2020: $1,594 · 2021: $1,650 · 2022: $9.50 · 2023: $2,305 · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,075 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,125 · Consulting Fee: $5,069 · Travel and Lodging: $3,919 · Honoraria: $2,025 · Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,075.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,125.00 |
| Consulting Fee | $5,068.75 |
| Travel and Lodging | $3,919.04 |
| Honoraria | $2,025.00 |
| Food and Beverage | $1,388.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $13,643.28 | 2021-2025 | Cabometyx |
| Coherus Oncology, INC. | $10,820.82 | 2024-2025 | Loqtorzi |
| Eisai INC. | $5,203.67 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $1,438.13 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $830.98 | 2019-2020 | |
| Astrazeneca Uk Limited | $735.09 | 2019 | |
| Janssen Biotech, INC. | $248.11 | 2024-2025 | Rybrevant, Tecvayli, Talvey |
| Regeneron Pharmaceuticals, INC. | $206.25 | 2023-2025 | Libtayo |
| Beigene USA, INC. | $129.26 | 2023 | Brukinsa |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siddharth Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.